Developing highly potent APIs: handling hazards
The development of highly potent active pharmaceutical ingredients is a difficult task for many. However, companies can adopt a number of practices to ensure a smoother, safer process.
The pharmaceutical industry’s ongoing search for new medicines capable of achieving greater therapeutic activity while also reducing dosage amounts and minimising undesirable side effects has led to an intense research focus on more potent drug molecules. As a result, the number of highly potent active pharmaceutical ingredients (HPAPIs) under development over the past few years has been steadily increasing, with HPAPIs present in around a quarter of medicines in the pharma pipeline.
This article is taken from Pharmaceutical Manufacturing and Packing Sourcer November 2017, pages 14-16. © Samedan Ltd.